Assigning new roles to topical tacrolimus.

Authors:Eustathios Rallis, Chrysovalantis Korfitis, Stamatis Gregoriou, Dimitris Rigopoulos
Language:Eng.
Date:09-08-2007
Journal:Expert opinion on investigational drugs (1744-7658)
Release:Expert Opin Investig Drugs. 2007 Aug;16(8):1267-76


Abstract:



Tacrolimus is an ascomycin macrolactam derivative with immunomodulatory and anti-inflammatory activity that belongs to the class of calcineurin inhibitors. Tacrolimus in its topical formulation has been established as a safe and effective alternative to topical corticosteroids because of its mild side effects and its minimal systemic absorption. Topical tacrolimus has been approved for the treatment of atopic dermatitis in two concentrations, 0.03 and 0.1%. In a thorough research of literature the authors review all of the available data regarding the off-label uses of the medication in other dermatoses. It seems that compared to pimecrolimus, tacrolimus has proved to be a more effective treatment. There is no causal relationship that has been established between tacrolimus and carcinogenesis. Furthermore, the authors believe that, without any evidence, the theoretical concerns are not enough to produce warnings. Tacrolimus ointment 0.1% may be recommended as a first-line choice for seborrheic dermatitis of the face and trunk, facial and intertriginous psoriasis and probably for allergic contact dermatitis and Zoon's balanitis. It has been ineffective in numerous dermatoses such as alopecia areata, necrobiosis lipoidica, internal pruritus and in thick hyperkeratotic plaques of psoriasis when administered as the commercially available formulation without occlusion. There is yet unexploited therapeutic potential regarding the use of topical tacrolimus in dermatology. Isolated cases of successful administration of the medication in various cutaneous conditions require further large-scale studies to clarify the actual effectiveness.

Copyright:Expert opinion on investigational drugs

University of Athens, Department of Dermatology, A. Sygros' Hospital, Athens, Greece.
Full text:
EBSCO - HTML (needs subscription)
Ingenta plc - HTML (needs subscription)
Swets Information Services - HTML (needs subscription)
Ashley Publications Ltd - (needs subscription)
Terms:Administration, Topical, Animals, Humans, Ointments, Tacrolimus
 
Add to my archiveAdd to my archive


Send to a friendSend to a friend
Expert opinion on investigational drugs